Evidence map›Paper›PMID 37218387›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

Subjective cognitive decline across ethnoracial groups in the A4 study.

Talia Robinson, Hannah Klinger, Rachel Buckley, Kacie D Deters, Yakeel T Quiroz, Dorene Rentz, Jennifer S Rabin, Reisa A Sperling, Rebecca E Amariglio

Open access · bronzeAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Subjective cognitive decline among diverse older adults: Prevalence and associations with objective cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Talia RobinsonDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-5655-8324
Hannah KlingerDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Rachel BuckleyDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Kacie D DetersCenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Yakeel T QuirozDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Dorene RentzDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Jennifer S RabinHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
Reisa A SperlingDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Rebecca E AmariglioDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Brigham and Women's Hospital · USHarvard University · USSunnybrook Health Science Centre · CA

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Hyun-Sik Yang · 2010 to 2026
$50.2M
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
The A3 Study: Ante-Amyloid Prevention of Alzheimer's diseaseR01AG054029 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., JOHNSON, KEITH A. · 2016 to 2023
$20.9M
Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's diseaseR01AG058825 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AMARIGLIO, REBECCA E · 2019 to 2024
$4.0M
Program to enrich translation and multimodal research in Alzheimers disease and related dementiasT32AG066592 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI PRICE, JULIE C · 2021 to 2025
$1.6M
NIA NIH HHS P01 AG036694NIA NIH HHS R01 AG053798NIA NIH HHS R01 AG054029NIA NIH HHS R01 AG058825NIA NIH HHS R01 AG063689NIA NIH HHS T32 AG066592NIA NIH HHS U24 AG057437
6 · The paper itself

Abstract

introductionThe associations between subjective cognitive decline (SCD), cognition, and amyloid were explored across diverse participants in the A4 study.

methodsFive thousand one hundred and fifty-one non-Hispanic White, 262 non-Hispanic Black, 179 Hispanic-White, and 225 Asian participants completed the Preclinical Alzheimer Cognitive Composite (PACC), self- and study partner-reported Cognitive Function Index (CFI). A subsample underwent amyloid positron emission tomography (

resultsThe associations between PACC-CFI and amyloid-CFI were moderated by race. The relationships were weaker or non-significant in non-Hispanic Black and Hispanic White groups. Depression and anxiety scores were stronger predictors of CFI in these groups. Despite group differences in the types of study partners, self- and study partner-CFI were congruent across groups. DISCUSSION: SCD may not uniformly relate to cognition or AD biomarkers in different ethnoracial groups. Nonetheless, self- and study partner-SCD were congruent despite differences in study partner type. Highlights Association between SCD and objective cognition was moderated by ethnoracial group. Association between SCD and amyloid was moderated by ethnoracial group. Depression and anxiety were stronger predictors of SCD in Black and Hispanic groups. Study-partner and self-reported SCD are congruent across groups. Study-partner report was consistent despite difference in study partner types.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersHumansNeuropsychological TestsPositron-Emission TomographySelf ReportAmyloid beta-PeptidesBiomarkerscognitionethnoracial differencespreclinical ADsubjective cognitive decline

Identifiers

PMID37218387
PMCPMC10524317
OpenAlexW4377564550

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.